Clear Up Confusion With Biosimilars

November 2022

Biosimilars will be in the spotlight again...with up to 12 biosimilars for adalimumab (Humira) slated for 2023.

Biosimilars aren’t generics. It’s not possible to create an exact copy of the original “reference” biologic...since biologics contain larger, more complex molecules than most traditional drugs.

Biosimilars must show no clinically meaningful differences from the reference biologic in safety, purity, and potency.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Controlled Substances Support Diversion Prevention From Purchasing to Disposal
Practice Don’t Let Patients Get Expired Meds
Influenza Limit Mishaps With Antiviral Meds for Flu
Critical Care Have Meds Ready for Rapid Sequence Intubation
Biosimilars Clear Up Confusion With Biosimilars
Anticoagulants Take Steps to Keep Patients on Warfarin Safe
Hyponatremia Ensure Safety With Hyponatremia Treatments
Emergency Medicine Don’t Be Surprised to See Some Injectables Used Intranasally
Supplements Document Use of Supplements for Osteoarthritis

Clear Up Confusion With Biosimilars

Practical advice for a better career, with unlimited access to CE

Table of Contents